Gennao Bio
BioTech/Drugs - Pennington, NJ, US
Gennao Bio Senior Management
Gary Sender
Independent Director of Public and Private Life Sciences Companies and CEO
Gennao Bio Details
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Gennao Bio Technologies
Captcha
reCAPTCHA
Email Providers
Outlook
Load Balancers
Nginx
CMS
WordPress.org
Other
Microsoft Office 365
Hosting
Google Cloud Hosting